Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1011)

SUPPLEMENTAL ANNOUNCEMENT
DISCLOSURE OF JUDICIAL PROCEDURE RECORDS OF A DIRECTOR

Reference is made to the announcement of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 8 May 2026 (the "**Announcement**") in relation to the disclosure of judicial procedure records of a director. The Company hereby provides the following supplemental disclosure:

Jiangsu Tailing Investment Co., Ltd. (江蘇泰凌投資有限公司) (a former subsidiary of the Company) was subject to a consumption restriction order (限制消費令) issued by the People's Court of Suzhou Industrial Park of Jiangsu Province (江蘇省蘇州工業園區人民法院) on 21 June 2023 in relation to a financial loan contract dispute with China Merchants Bank Co., Ltd. Suzhou Branch (招商銀行股份有限公司蘇州分行) (Case No.: (2022) Su 0591 Zhi 4540). The case originated from the Civil Mediation Document (民事調解書) No. (2022) Su 05 Min Chu 224 issued by the Suzhou Intermediate People's Court of Jiangsu Province (江蘇省蘇州市中級人民法院), involving a principal loan amount of RMB119 million, which was secured by a mortgage by way of maximum amount security (最高額抵押擔保) over real property owned by Suzhou First Pharmaceutical Co., Ltd. (蘇州第壹製藥有限公司) ("**Suzhou First Pharma**"). Mr. Ng Tit (吳鐵先生) ("**Mr. Ng**"), as the then legal representative of Jiangsu Tailing Investment Co., Ltd., became subject to consumption restrictions in accordance with the relevant PRC laws.

On 5 December 2022, the People's Court of Suzhou Industrial Park of Jiangsu Province decided to refer the enforcement proceedings against Suzhou First Pharma as the judgment debtor for bankruptcy reorganization review and suspended the enforcement against Suzhou First Pharma. On 27 April 2023, the court ruled to accept the bankruptcy reorganization application of Suzhou First Pharmaceutical Co., Ltd. (Case No.: (2023) Su 0591 Po 61). Upon verification by the Company's PRC legal adviser, in the course of such bankruptcy reorganization proceedings, China Merchants Bank Suzhou Branch, as a secured creditor with specific property security, has been satisfied on a priority basis in respect of the collateral owned by Suzhou First Pharma in accordance with the law, and the aforesaid principal debt of RMB119 million has been settled in full. Accordingly, the enforcement proceedings under Case No. (2022) Su 0591 Zhi 4540 have been incorporated into the bankruptcy reorganization proceedings for unified handling, and the principal debt involved therein has been settled in full.

These records arose because Mr. Ng had served as the legal representative of certain subsidiaries of the Group and/or had provided personal guarantees in respect of indebtedness of the Group's subsidiaries, and were not attributable to any personal misconduct or financial impropriety on the part of Mr. Ng.

The above matters are not expected to have any material adverse impact on the daily business operations and financial position of the Group or the ability of Mr. Ng to discharge his duties as a director.

By Order of the Board
China NT Pharma Group Company Limited
Chairman
Ng Tit

Hong Kong, 15 May 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.